Quantcast

Latest JN-International Medical Corporation Stories

2014-05-19 08:28:56

DUBLIN, May 19, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/rd8s6p/meningococcal) has announced the addition of the "Global Meningococcal Vaccines Market - Forecasts to 2019: Sanofi, Novartis, GlaxoSmithKline, Pfizer, Serum Institute of India, JN-International, Nuron, Baxter and Biomed" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 Meningococcal disease caused by the bacterium Neisseria meningitidis is a life...

2012-06-05 11:21:11

A new technique that accurately determines the risk of infants in endemic countries developing clinical malaria could provide a valuable tool for evaluating new malaria prevention strategies and vaccines. The technique could even help to understand how anti-malarial vaccine and treatment strategies act to reduce malaria, say researchers from the Walter and Eliza Hall Institute, Swiss Tropical and Public Health Institute, University of Basel and the Papua New Guinea Institute of Medical...

2011-05-17 11:00:00

SAN DIEGO, May 17, 2011 /PRNewswire/ -- Pfenex Inc.'s Reagent Proteins division announced today that it has submitted a Biologics Master File (BMF) to the United States Food and Drug Administration for its cGMP grade CRM197 carrier protein to support the development of conjugate vaccine products by its partners. Reagent Proteins is supplying cGMP grade CRM197 carrier protein to multiple partners in support of their novel conjugate vaccine development efforts. As part of the product...

2010-04-18 23:01:00

ROCKVILLE, Md., April 19 /PRNewswire/ -- Protein Potential LLC has received support from the National Institute of Allergy and Infectious Diseases (NIAID) of the NIH in the form of a Phase II Small Business Innovation Research (SBIR) Grant. The three-year award totaling approximately $3 million will support translational research to develop a vaccine for the prevention of malaria caused by the parasite Plasmodium vivax. Approximately 40% of the world's population is at risk from malaria...

2008-10-17 03:00:00

Dutch biopharma company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) and the Aeras Global TB Vaccine Foundation today announce the start of a Phase I clinical trial in Kenya of the jointly developed tuberculosis (TB) vaccine candidate, AERAS-402/Crucell Ad35. The announcement is made in the lead up to the 39th Union World Conference on Tuberculosis and Lung Disease in Paris, France (16-20 October, 2008). This first-ever study of the new...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related